NDA News

CanalLotus Biotech news and insights

FDA Approves Wilserdly (giredestrant) for ER-Positive, ESR1-Mutated Advanced Breast Cancer

South San Francisco, CA -- November 16, 2026 -- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the United States (U.S.) Food and Drug Administration (FDA) ha

Latest News NDA News 33
• Read All

FDA Approves Klygefa (gefurulimab) for the Treatment of Generalised Myasthenia Gravis

16 November 2026 -- Alexion, AstraZeneca Rare Disease’s Klygefa (gefurulimab) has been approved in the US for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetyl

Latest News NDA News 63
• Read All

FDA Approves Pebrilzo (pertuzumab-qcay), a Biosimilar to Perjeta

BENGALURU, India and BRIDGEWATER, N.J., United States: November 16, 2026 -- Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, today announced that the U.S.

Latest News NDA News 99
• Read All

FDA Approves Pimjetmi (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor

November 10, 2026 -- EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved Pimjetmi

Latest News NDA News 169
• Read All

FDA Approves Sunharbo (asundexian) in Combination with Antiplatelet Therapy for Secondary Stroke Prevention

WHIPPANY, N.J.-- November 9, 2026 -- Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved Sunharbo® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa

Latest News NDA News 231
• Read All

FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis

PLYMOUTH MEETING, Pa., Oct. 30, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rel

Latest News NDA News 246
• Read All

FDA Approves Lucamzi (ranibizumab-blrz), a Biosimilar to Lucentis

Solna, Sweden 27 October 2026 -- Lucamzi™ (ranibizumab-blrz) biosimilar to Lucentis® has been approved by FDA in the US. Xbrane will finalize preparation for an upcoming launch of the product during 2

Latest News NDA News 288
• Read All

FDA Approves Hibsago (bepirovirsen) for the Treatment of Chronic Hepatitis B

London, UK -- 20 October 2026 -- GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CH

Latest News NDA News 317
• Read All

FDA Approves Brytly (apraclonidine) Ophthalmic Solution for Relief of Eye Redness

GENEVA--(BUSINESS WIRE) October 16, 2026 -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that the U.S. Food and Drug Administration

Latest News NDA News 273
• Read All

FDA Approves Hovilpri (pritelivir) for the Treatment of Mucocutaneous Herpes Simplex Virus (HSV) Lesions

Tokyo – October 10, 2026 -- Asahi Kasei Therapeutics, Inc., the global specialty pharmaceutical business of Tokyo-based Asahi Kasei, with U.S. and European business headquarters in Cary, North Carolin

Latest News NDA News 346
• Read All

FDA Approves Weltruza (olanzapine) Once-Monthly Subcutaneous Injection for the Treatment of Adults with Schizophrenia

PARSIPPANY, N.J. and TEL AVIV, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.

Latest News NDA News 313
• Read All

FDA Approves Emcitate (tiratricol) for the Treatment of Patients with MCT8 Deficiency

STOCKHOLM, SWEDEN, Sept. 28 2026. (GLOBE NEWSWIRE) -- Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX) today announced that the U.S. Food and Drug

Latest News NDA News 306
• Read All
News
Gloved hands holding a globe, global clinical trial drug sourcing
- CanalLotus Biotech -
Int'l Clinical Service Expert

We are the leader
Because of our professionism

WhatsApp Service QR code